# EDGAR Filing Document

**Accession Number:** 0001503274
**File Stem:** 0001503274-25-000069
**Filing Date:** 2025-7
**Character Count:** 63417
**Document Hash:** 9a5ae1eca450c995d643900e491e83c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001503274-25-000069.hdr.sgml**: 20250711

**ACCESSION NUMBER**: 0001503274-25-000069

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20250711

**DATE AS OF CHANGE**: 20250711

**EFFECTIVENESS DATE**: 20250711

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quanterix Corp
- **CENTRAL INDEX KEY:** 0001503274
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208957988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288648
- **FILM NUMBER:** 251119571

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 617-301-9400

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

As filed with the Securities and Exchange Commission on July 11, 2025

Registration No. 333-_____

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER**

**THE SECURITIES ACT OF 1933**

**QUANTERIX CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **20-8957988** |
| (State or other jurisdiction of incorporation or<br>organization) | (I.R.S. Employer Identification No.) |
| **900 Middlesex Turnpike** | |
| **Billerica, MA** | **01821** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Akoya Biosciences, Inc. 2021 Equity Incentive Plan**

**Quanterix Corporation Restricted Stock Unit Inducement Awards**

(Full title of the plans)

**Masoud Toloue, Ph.D.**

**President and Chief Executive Officer**

**Quanterix Corporation**

**900 Middlesex Turnpike**

**Billerica, MA 01821**

**(617) 301-9400**<br> (Name, address and telephone number, including area code, of agent for service)

**Copies to:**

---

| | |
|:---|:---|
| **Kerry S. Burke**<br>**Catherine Dargan**<br>**Kyle Rabe<br>Covington & Burling LLP**<br>**One CityCenter<br>850 Tenth Street, N.W.<br>Washington, D.C. 20001**<br>**(202) 662-6000** | **Laurie Churchill<br>General Counsel<br>Quanterix Corporation<br>900 Middlesex Turnpike<br>Billerica, MA 01821<br>(617) 301-9400** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

------

---

| | |
|:---|:---|
| Large accelerated filer  | Accelerated filer  |
| Non-accelerated filer  | Smaller reporting company  |
| | Emerging growth company  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

**EXPLANATORY NOTE**

Quanterix Corporation ("Quanterix" or the "Registrant") is filing this Registration Statement on Form S-8 (the "Registration Statement") in connection with the merger (the "Merger") of Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix ("Merger Sub"), with and into Akoya Biosciences, Inc. ("Akoya"), with Akoya surviving as a wholly owned subsidiary of Quanterix in the Merger. At the effective time of the Merger (the "Effective Time"), each share of common stock of Akoya ("Akoya Common Stock"), $0.00001 par value per share, outstanding immediately prior to the Effective Time was converted into the right to receive (a) 0.1470 of a share of the common stock of Quanterix ("Quanterix Common Stock"), par value $0.001 per share (the "Per Share Stock Consideration") and, if applicable, cash in lieu of fractional shares, and (b) $0.37 in cash, without interest (the "Per Share Cash Consideration" and, together with the Per Share Stock Consideration, the "Per Share Merger Consideration").

This Registration Statement registers an aggregate of 520,450 shares of Quanterix Common Stock, consisting of: (i) up to 253,181 shares of Quanterix Common Stock that may be become available for issuance again under the 2021 Akoya Equity Incentive Plan pursuant to the terms of such plan and (ii) 267,269 shares of Quanterix Common Stock issuable upon vesting of restricted stock units granted to Akoya employees as an inducement to employment with Quanterix following the Merger pursuant to Nasdaq Listing Rule 5635(c)(4) (the "Restricted Stock Unit Inducement Awards"). This Registration Statement shall also cover any additional shares of Quanterix Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of outstanding shares of Quanterix Common Stock.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS**

**Item 1. Plan Information.\***

**Item 2. Registrant Information and Employee Plan Annual Information.\*** 

\* In accordance with Rule 428 under the Securities Act and the Note to Part I of Form S-8, the information required by this Part I of Form S-8 is not and will not be filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance therewith files reports, proxy

------

statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Quanterix's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 17, 2025, as amended by Amendment No. 1, filed with the Commission on April 30, 2025 (File No. 001-38319);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Quanterix's Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the Commission on May 12, 2025 (File No. 001-38319);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Quanterix's Current Reports on Form 8-K, filed with the Commission on January 8, 2025, January 10, 2025, January 31, 2025, February 25, 2025, March 28, 2025, April 4, 2025, April 29, 2025, May 12, 2025, May 14, 2025, July 1, 2025 and July 8, 2025 (except for any portions of such Current Reports on Form 8-K furnished pursuant to Item 2.02 and/or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) (File No. 001-38319); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The description of Common Stock filed as Exhibit 4.1 to Quanterix's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 13, 2020 (File No. 001-38319).

In addition, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment hereto that indicates that all securities offered hereunder have been sold or deregisters all securities then remaining unsold, all reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents; provided, however, that no information furnished (but not filed) under Item 2.02 or Item 7.01 of any Current Report on Form 8-K and any corresponding exhibits thereto not filed with the Commission shall be incorporated by reference except to the extent specified in such Current Report on Form 8-K.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not Applicable.

**Item 5. Interests of Named Experts and Counsel.**

The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Registrant by Covington & Burling LLP.

**Item 6. Indemnification of Directors and Officers.**

Section 145(a) of the Delaware General Corporation Law (the "DGCL") provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

------

Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.

Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.

The Registrant's restated certificate of incorporation (the "Charter") provides that no director of the Registrant shall be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (1) for any breach of the director's duty of loyalty to the Registrant or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) in respect of unlawful dividend payments or stock redemptions or repurchases, or (4) for any transaction from which the director derived an improper personal benefit. In addition, the Charter provides that if the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of the Registrant shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

The Charter further provides that any repeal or modification of such article by the Registrant's stockholders or amendment to the DGCL will not adversely affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director serving at the time of such repeal or modification.

The Registrant's restated bylaws (the "Bylaws") provide that the Registrant will indemnify each of its directors and officers and, in the discretion of its board of directors, certain employees, to the fullest extent permitted by the DGCL as the same may be amended (except that in the case of amendment, only to the extent that the amendment permits the Registrant to provide broader indemnification rights than the DGCL permitted it to provide prior to such the amendment) against any and all expenses, judgments, penalties, fines and amounts reasonably paid in settlement that are incurred by the director, officer or such employee or on the director's, officer's or employee's behalf in connection with any threatened, pending or completed proceeding or any claim, issue or matter therein, to which he or she is or is threatened to be made a party because he or she is or was serving as a director, officer or employee of the Registrant, or at the Registrant's request as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Bylaws further provide for the advancement of expenses to each of the directors and officers and, in the discretion of the board of directors, to certain employees and agents.

In addition, the Bylaws provide that the right of each of the Registrant's directors and officers to indemnification and advancement of expenses shall be a contract right and shall not be exclusive of any other right now possessed or hereafter acquired under any statute, provision of the Charter or Bylaws, agreement, vote of stockholders or otherwise. Furthermore, the Bylaws authorize the Registrant to provide insurance for its directors,

------

officers, employees and agents against any liability, whether or not it would have the power to indemnify such person against such liability under the DGCL or the provisions of our Bylaws.

The Registrant has also entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify each of its directors and such officers to the fullest extent permitted by law and the Charter and Bylaws.

The Registrant also maintains a general liability insurance policy, which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

The foregoing discussion of the Charter, Bylaws, indemnification agreements and the DGCL is not intended to be exhaustive and is qualified in its entirety by such Charter, Bylaws, indemnification agreements or law.

**Item 7. Exemption from Registration Claimed.**

Not Applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| &nbsp;&nbsp;3.1 | <u>[Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on December 15, 2017).](https://www.sec.gov/Archives/edgar/data/1503274/000110465917073618/a17-28479_1ex3d1.htm)</u> |
| &nbsp;&nbsp;3.2 | <u>[Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 of the Registrant's Quarterly Report on Form 10-Q filed on August 8, 2023).](https://www.sec.gov/Archives/edgar/data/1503274/000110465917073618/a17-28479_1ex3d2.htm)</u> |
| &nbsp;&nbsp;4.1 | <u>[Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 of the Registrant's Registration Statement on Form S-1 filed on November 9, 2017).](https://www.sec.gov/Archives/edgar/data/1503274/000104746917006947/a2233678zex-4_1.htm)</u> |
| &nbsp;&nbsp;4.2\* | <u>[Form of Inducement Award Grant Notice and Inducement Award Grant Agreement (RSUs).](ex42_grantnotice.htm)</u> |
| &nbsp;&nbsp;5.1\* | <u>[Opinion of Covington and Burling LLP.](exhibit51-covingtonopinion.htm)</u> |
| &nbsp;&nbsp;23.1\* | <u>[Consent of Covington and Burling LLP (included in Exhibit 5.1).](exhibit51-covingtonopinion.htm)</u> |
| &nbsp;&nbsp;23.2\* | <u>[Consent of Ernst & Young LLP.](exhibit232-eysx8consent.htm)</u> |
| &nbsp;&nbsp;24.1\* | <u>[Power of Attorney (included on the signature page of this Registration Statement).](#id4b9d29aaed54682aeaf7eee3959743f_19)</u> |
| &nbsp;&nbsp;99.1 | <u>[Akoya Biosciences, Inc. 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Form S-1 of Akoya Biosciences, Inc. filed on March 26, 2021).](https://www.sec.gov/Archives/edgar/data/1711933/000110465921049062/tm212065d11_ex10-2.htm)</u> |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;99.2 | <u>[Form of Stock Option Grant Notice and Stock Option Agreement for 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Form S-8 of Akoya Biosciences, Inc. filed on March 17, 2025).](https://www.sec.gov/Archives/edgar/data/1711933/000110465925024422/tm259213d1_ex99-3.htm)</u> |
| &nbsp;&nbsp;99.3 | <u>[Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.4 to the Form S-8 of Akoya Biosciences, Inc. filed on March 17, 2025).](https://www.sec.gov/Archives/edgar/data/1711933/000110465925024422/tm259213d1_ex99-4.htm)</u> |
| &nbsp;&nbsp;107\* | <u>[Filing Fees Exhibit.](exhibit107-sx8feetable.htm)</u> |

---

____________

\* Filed herewith.

**Item 9. Undertakings**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee" table in the effective Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

Provided, however, that paragraphs (1)(i) and (1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the indemnification provisions summarized in Item 6, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

*The Registrant.* Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Billerica, Commonwealth of Massachusetts, on July 11 , 2025.

---

| | |
|:---|:---|
| QUANTERIX CORPORATION | QUANTERIX CORPORATION |
| By: | /s/ Masoud Toloue |
|  | Masoud Toloue |
|  | *President and Chief Executive Officer* |

---

**SIGNATURES AND POWER OF ATTORNEY**

Each of the directors and officers of Quanterix Corporation whose signature appears below hereby severally constitutes and appoints Masoud Toloue and Vandana Sriram and each of them singly, their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for them and in their name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Quanterix Corporation, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| <br>/s/ Masoud Toloue, Ph.D. | President, Chief Executive Officer and Director (principal executive officer) | July 11, 2025 |
| Masoud Toloue, Ph.D. | President, Chief Executive Officer and Director (principal executive officer) | July 11, 2025 |
| /s/ Vandana Sriram | Chief Financial Officer (principal financial officer and principal accounting officer) | July 11, 2025 |
| Vandana Sriram | Chief Financial Officer (principal financial officer and principal accounting officer) | July 11, 2025 |
| /s/ William Donnelly | Director | July 11, 2025 |
| William Donnelly |  |  |
| /s/ Jeffrey T. Elliott | Director | July 11, 2025 |
| Jeffrey T. Elliot |  |  |
| /s/ Karen A. Flynn | Director | July 11, 2025 |
| Karen A. Flynn |  |  |
| /s/ Ivana Magovčević-Liebisch, Ph.D., J.D. | Director | July 11, 2025 |
| Ivana Magovčević-Liebisch, Ph.D., J.D. |  |  |
| /s/ Paul M. Meister | Director | July 11, 2025 |
| Paul M. Meister |  |  |
| /s/ David R. Walt, Ph.D. | Director | July 11, 2025 |
| David R. Walt, Ph.D. |  |  |
| /s/ Myla Lai-Goldman M.D. | Director | July 11, 2025 |
| Myla Lai-Goldman M.D. |  |  |
| /s/ Scott Mendel | Director | July 11, 2025 |
| Scott Mendel |  |  |

---

## Ex-Filing

**EXHIBIT 107**

**Calculation of Filing Fee Tables** 

Form S-8

(Form Type)

Quanterix Corporation

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| (1) | **Security** <br>**Type** | **Security Class Title** | **Fee**<br>**Calculation**<br>**Rule** | **Amount**<br>**Registered(1)** | **Proposed Maximum Offering**<br>**Price Per Unit(2)** | **Maximum Aggregate**<br>**Offering Price(2)** | **Fee**<br>**Rate** | **Amount of**<br>**Registration**<br>**Fee** |
| (2) | Equity | Common Stock, par value $0.001 per share, to be issued under the Akoya Biosciences, Inc. 2021 Equity Incentive Plan | Other | 253181 (3) | $5.983 | $1514782 | $153.10 per $1,000,000 | $231.91 |
| (3) | Equity | Common Stock, par value $0.001 per share, to be issued pursuant to restricted stock unit inducement awards | Other | 267269 (4) | $5.983 | $1599070 | $153.10 per $1,000,000 | $244.82 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $3113852 |  | $476.73 |
| (4) | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $— |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $476.73 |

---

(1) This Registration Statement on Form S-8 (this "Registration Statement") covers shares of common stock, par value $0.001 per share ("Common Stock"), of Quanterix Corporation (i) authorized for issuance under the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the "Assumed Plan") and (ii) pursuant to Quanterix Corporation's restricted stock unit inducement awards to 20 new employees. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock that become issuable in respect of such securities by reason of any stock dividend, stock split, recapitalization or other similar transaction.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, and based upon the average of the high and low prices of the registrant's Common Stock as reported on The Nasdaq Global Market on March 17, 2025.

(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act, and based upon the average of the high and low prices of the registrant's Common Stock as reported on The Nasdaq Global Market on July 10, 2025.

(4) The registrant does not have any fee offsets.

## Exhibit 4.2

**Exhibit 4.2**

Restricted Stock Unit No.________

**QUANTERIX CORPORATION**

**Inducement Award Grant Notice** 

1.&nbsp;&nbsp;&nbsp;&nbsp;Name and Address of Recipient:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;("<u>Recipient</u>")&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

2.&nbsp;&nbsp;&nbsp;&nbsp;Date of Grant ("<u>Grant Date</u>") of

&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Unit Award:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

3.&nbsp;&nbsp;&nbsp;&nbsp;Maximum Number of Shares underlying

&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Unit Award:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

4.&nbsp;&nbsp;&nbsp;&nbsp;Vesting of Award: This award of restricted stock units ("<u>Restricted Stock Unit Award</u>") shall vest in full on the first anniversary of the Grant Date provided the Recipient is an employee of the Company or of a subsidiary of the Company on such anniversary date.

The Company and the Recipient acknowledge receipt of this Inducement Award Grant Notice and agree to the terms of the Inducement Award Grant Agreement (RSUs) attached hereto and incorporated by reference herein and the terms of this Restricted Stock Unit Award as set forth above.

**&nbsp;&nbsp;&nbsp;&nbsp;**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUANTERIX CORPORATION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recipient

------

**QUANTERIX CORPORATION** 

**<u>Inducement Award Grant Agreement (RSUs)</u>**

**<u>Incorporated Terms and Conditions</u>**

THIS AGREEMENT (this "<u>Agreement</u>") made as of the date of grant set forth in the Inducement Award Grant Notice between QUANTERIX CORPORATION (the "<u>Company</u>"), a Delaware corporation, and the individual whose name appears on the Inducement Award Grant Notice (the "<u>Recipient</u>").

WHEREAS, the Company desires to grant to the Recipient restricted stock units ("<u>RSUs</u>") related to the Company's common stock, $0.001 par value per share ("<u>Common Stock</u>") as an inducement to employment with the Company (or any of its subsidiaries) and on the terms and conditions hereinafter set forth; and

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Award</u>. The Company hereby grants to the Recipient an award for the number of RSUs set forth in the Inducement Award Grant Notice (the "<u>Award</u>"). Each RSU represents a contingent entitlement of the Recipient to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein. The Award is intended to constitute an "employment inducement award" and to be exempt from shareholder approval requirements under Rule 5635(c)(4) of the Nasdaq Listing Rules, and this Agreement and the terms and conditions of the Award will be interpreted consistent with such intent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting of Award; Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement, the Award granted hereby shall vest as set forth in the Inducement Award Grant Notice and is subject to the other terms and conditions of this Agreement. On the vesting date set forth in the Inducement Award Grant Notice, the Recipient shall be entitled to receive such number of shares of Common Stock equivalent to the number of RSUs as set forth in the Inducement Award Grant Notice provided that the Recipient is employed by the Company or a subsidiary of the Company (an "<u>Affiliate</u>") on such vesting date. Such shares of Common Stock shall thereafter be delivered by the Company to the Recipient within five days of the applicable vesting date and in accordance with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise set forth in this Agreement, if the Recipient ceases for any reason to be employed by the Company or by an Affiliate (the "<u>Termination</u>") prior to the vesting date set forth in the Inducement Award Grant Notice, then as of the date on which the Recipient's employment terminates, all unvested RSUs shall immediately be forfeited to the Company and this Agreement shall terminate and be of no further force or effect.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Prohibitions on Transfer and Sale</u>. This Award (including any additional RSUs received by the Recipient as a result of stock dividends, stock splits or any other similar transaction affecting the Company's securities without receipt of consideration) shall not be transferable by the Recipient otherwise than (i) by will or by the laws of descent and distribution, or (ii) pursuant to a qualified domestic relations order as defined by the Internal Revenue Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except as provided in the previous sentence, the shares of Common Stock to be issued pursuant to this Agreement shall be issued, during the Recipient's lifetime, only to the Recipient (or, in the event of legal incapacity or incompetence, to the Recipient's guardian or representative). This Award shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 3, or the levy of any attachment or similar process upon this Award shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u>. Upon the occurrence of any of the following events, a Recipient's rights with respect to any Award granted to him or her hereunder shall be adjusted as hereinafter provided:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Stock Dividends and Stock Splits</u>. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock, this Award and the number of shares of Common Stock deliverable hereunder shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made to reflect such events.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Corporate Transactions</u>. If the Company is to be consolidated with or acquired by another entity in a merger, consolidation, sale of all or substantially all of the Company's assets or the acquisition of all of the outstanding voting stock of the Company in a single transaction or a series of related transactions other than a transaction to merely change the state of incorporation (a "<u>Corporate Transaction</u>"), the Administrator (as hereinafter defined) or the board of directors of any entity assuming the obligations of the Company hereunder (the "<u>Successor Board</u>"), shall make appropriate provision for the continuation of this Award on the same terms and conditions by substituting on an equitable basis for the shares then subject to this Award either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator may provide that, upon consummation of the Corporate Transaction, this Award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock comprising this Award (to the extent this Award is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon such Corporate Transaction). In taking any of the actions permitted under this

------

subparagraph, the Administrator shall not be obligated to treat this Award identically to any other awards of the same type.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Recapitalization or Reorganization; Dissolution or Liquidation</u>. In the event of a recapitalization or reorganization of the Company other than a Corporate Transaction pursuant to which securities of the Company or of another corporation or other entity are issued with respect to the outstanding shares of Common Stock, a Recipient upon accepting this Award after the recapitalization or reorganization shall be entitled to receive for the price paid upon acceptance if any, the number of replacement securities which would have been received if this Award had been accepted prior to such recapitalization or reorganization. Upon the dissolution or liquidation of the Company, the Award shall immediately terminate unless otherwise determined by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Adjustments to the Award</u>. Upon the happening of any of the events described in subparagraphs (a), (b) or (c) above, this Award (if outstanding) shall be appropriately adjusted to reflect the events described in such subparagraphs. The Administrator or the Successor Board shall determine the specific adjustments to be made under this paragraph 4, including, but not limited to, the effect of any Corporate Transaction and its determination shall be conclusive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Issuances of Securities</u>. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares subject to this Award. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of shares pursuant to this Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Law Compliance</u>. The Recipient specifically acknowledges and agrees that any sales of shares of Common Stock shall be made in accordance with the requirements of the Securities Act of 1933, as amended. The Company intends to file a registration statement with the Securities and Exchange Commission with respect to the Common Stock to be granted hereunder. The Company intends to maintain this registration statement but has no obligation to do so. If the registration statement ceases to be effective for any reason, Recipient will not be able to transfer or sell any of the shares of Common Stock issued to the Recipient pursuant to this Agreement unless exemptions from registration or filings under applicable securities laws are available. Furthermore, despite registration, applicable securities laws may restrict the ability of the Recipient to sell his or her Common Stock, including due to the Recipient's affiliation with the Company. The Company shall not be obligated to either issue the Common Stock or permit the resale of any shares of Common Stock if such issuance or resale would violate any applicable securities law, rule or regulation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights as a Stockholder</u>. The Recipient shall have no right as a stockholder, including voting and dividend rights, with respect to the RSUs subject to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Administration</u>. "<u>Administrator</u>" means the Board of Directors (the "<u>Board</u>") of the Company, unless it has delegated power to act on its behalf to the Compensation Committee

------

(the "<u>Committee</u>") of the Board, in which case the term "Administrator" means the Committee or its delegee. The Administrator is authorized to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Interpret the provisions of this Agreement and the Award and to make all rules and determinations which it deems necessary or advisable for the administration of this Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Amend any term or condition of this Award, provided that any such amendment shall not impair the rights of the Recipient without the Recipient's consent or, in the event of death of the Recipient, the Recipient's legal representatives and/or any person or persons who acquire the Recipient's rights to the Award by will or by the laws of descent and distribution, and any such amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the Recipient, including, but not limited to pursuant to Section 409A of the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto (the "<u>Code</u>"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Buy out for a payment in cash or shares of Common Stock, the Award and/or cancel the Award and grant in substitution therefor other stock rights, covering the same or a different number of shares of Common Stock, based on such terms and conditions as the Administrator shall establish and the Recipient shall accept;

provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of not causing any adverse tax consequences under Section 409A of the Code. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the Award shall be final, unless otherwise determined by the Board, if the Administrator is the Committee. In addition, if the Administrator is the Committee, the Board may take any action hereunder that would otherwise be the responsibility of the Committee.

To the extent permitted under applicable law, the Board or the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board or the Committee may revoke any such allocation or delegation at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Liability of the Recipient and Payment of Taxes</u>. The Recipient acknowledges and agrees that any income or other taxes due from the Recipient with respect to this Award or the shares of Common Stock to be issued pursuant to this Agreement or otherwise sold shall be the Recipient's responsibility. Without limiting the foregoing, the Recipient agrees that if under applicable law the Recipient will owe taxes at vesting, the Company shall be entitled to immediate payment from the Recipient of the amount of any tax or other amounts required to be withheld by the Company by applicable law or regulation. Any taxes or other amounts due shall be paid, at the option of the Administrator, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;through reducing the number of shares of Common Stock entitled to be issued to the Recipient on the applicable vesting date in an amount sufficient to cover the statutory minimum of the Recipient's total tax and other withholding obligations due and payable

------

by the Company. Only whole shares will be withheld to satisfy the Company's withholding obligation; fractional shares will not be withheld. Accordingly, the Recipient agrees that in the event that the value of the whole shares withheld would exceed the amount of the Company's withholding obligation, that excess will be refunded to the Recipient through a subsequent paycheck;

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;requiring the Recipient to deposit with the Company an amount of cash equal to the amount determined by the Company to be required to be withheld with respect to the statutory minimum amount of the Recipient's total tax and other withholding obligations due and payable by the Company or otherwise withholding from the Recipient's paycheck an amount equal to such amounts due and payable by the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;if the Company believes that the sale of shares can be made in compliance with applicable securities laws, authorizing, at a time when the Recipient is not in possession of material nonpublic information, the sale by the Recipient on the applicable vesting date of such number of shares of Common Stock as the Company instructs a registered broker to sell to satisfy the Company's withholding obligation, after deduction of the broker's commission, and the broker shall be required to remit to the Company the cash necessary in order for the Company to satisfy its withholding obligation. To the extent the proceeds of such sale exceed the Company's withholding obligation, the Company agrees to pay such excess cash to the Recipient as soon as practicable. In addition, if such sale is not sufficient to pay the Company's withholding obligation the Recipient agrees to pay to the Company as soon as practicable, including through additional payroll withholding, the amount of any withholding obligation that is not satisfied by the sale of shares of Common Stock. The Recipient agrees to hold the Company and the broker harmless from all costs, damages or expenses relating to any such sale. The Recipient acknowledges that the Company and the broker are under no obligation to arrange for such sale at any particular price. In connection with such sale of shares of Common Stock, the Recipient shall execute any such documents requested by the broker in order to effectuate the sale of shares of Common Stock and payment of the withholding obligation to the Company. The Recipient acknowledges that this paragraph is intended to comply with Section 10b5-1(c)(1(i)(B) under the United States Securities Exchange Act of 1934, as amended.

The Company shall not deliver any shares of Common Stock to the Recipient until it is satisfied that all required withholdings have been made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Recipient Acknowledgements and Authorizations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;The Recipient acknowledges the following:

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company is not by virtue of this Award obligated to continue the Recipient as an employee of the Company or an Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award, benefits in lieu of awards or any other benefits in the future. Future awards, if any, will be at the sole discretion of the Company,

------

including, but not limited to, the timing of any grant, the amount of any award, vesting provisions and the purchase price, if any.

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;The value of this Award is an extraordinary item of compensation outside of the scope of the Recipient's employment. As such the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;The Recipient (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering this Award or providing recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration hereof; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notices required or permitted by the terms of this Agreement shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:

If to the Company:

Quanterix Corporation

900 Middlesex Turnpike, Building 1

Billerica, MA 01821

Attention: General Counsel

&nbsp;&nbsp;&nbsp;&nbsp;

If to the Recipient, at the address set forth on the Inducement Award Grant Notice or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given on the earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by registered or certified mail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment and Successors</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is personal to the Recipient and without the prior written consent of the Company shall not be assignable by the Recipient otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Recipient's legal representatives.

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of the Commonwealth of Massachusetts or the federal courts of the United States for the District of Massachusetts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications and Amendments; Waivers and Consents</u>. Except as provided in paragraph 7 hereof, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>. The Award of RSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Section 409A of the Code as a "short term deferral" (as that term is used in the final regulations and other guidance issued under Section 409A of the Code, including Treasury Regulation Section 1.409A-1(b)(4)(i)), and shall be construed accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Clawback</u>. Notwithstanding anything to the contrary contained in this Agreement, the Company may recover from the Recipient any compensation received from the Award (whether or not settled) or cause the Recipient to forfeit the Award (whether or not vested) in the event that the Company's Clawback Policy then in effect is triggered.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

------

## Exhibit 5.1

**Exhibit 5.1**

![image.jpg](image.jpg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![image1.jpg](image1.jpg)

July 11, 2025

Quanterix Corporation

900 Middlesex Turnpike

Billerica, MA 01821

Ladies and Gentlemen:

We have acted as counsel to Quanterix Corporation, a Delaware corporation (the "*Company*"), and are rendering this opinion in connection with the registration by the Company under the Securities Act of 1933 (the "*Securities Act*"), of the offer and sale of (i) up to 253,181 shares of the Company's common stock, par value $0.001 per share (the "*2021 Plan Shares*"), that may become available for issuance pursuant to the terms of the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the "*Assumed Plan*"), which was assumed by the Company in connection with the consummation of the transactions contemplated by the Amended and Restated Agreement and Plan of Merger, dated as of April 28, 2025, by and among the Company, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc., and (ii) 267,269 shares of the Company's common stock, par value $0.01 per share (the "*Inducement Shares*" and together with the 2021 Plan Shares, the "*Shares*"), issuable upon the vesting of restricted stock units granted to employees of Akoya as an inducement to employment with the Company, in each case pursuant to the registration statement on Form S-8 filed with the United States Securities and Exchange Commission (the "*Commission*") on the date hereof (the "*Registration Statement*").

We have reviewed the Registration Statement, the Assumed Plan, the Form of Restricted Stock Unit Inducement Award, the Amended and Restated Certificate of Incorporation of the Company, and the Amended and Restated By-laws of the Company.

We have also reviewed such corporate records, certificates and other documents, and such questions of law, as we have deemed necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.

We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.

Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, the Shares, when duly issued and sold as contemplated in the Registration Statement, will be validly issued, fully paid and non-assessable.

We are members of the bar of the District of Columbia. We do not express any opinion herein on any laws other than the Delaware General Corporation Law and reported judicial decisions interpreting such law.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also hereby consent to the reference to our firm under the heading "Interests of Named Experts and Counsel" in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Covington & Burling LLP

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan and the Quanterix Corporation Restricted Stock Unit Inducement Awards plan of Quanterix Corporation of our reports dated March 17, 2025, with respect to the consolidated financial statements of Quanterix Corporation and the effectiveness of internal control over financial reporting of Quanterix Corporation included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

July 11, 2025

<br>